HC Wainwright Issues Positive Outlook for LXRX Earnings

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – HC Wainwright lifted their Q3 2026 EPS estimates for shares of Lexicon Pharmaceuticals in a research note issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($0.04) per share for the quarter, up from their prior estimate of ($0.05). The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.15) EPS and FY2027 earnings at ($0.20) EPS.

Several other brokerages have also recently issued reports on LXRX. Weiss Ratings raised Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Citigroup upped their price target on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the company a “buy” rating in a research report on Monday, May 11th. Zacks Research cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.55.

Lexicon Pharmaceuticals Stock Up 1.3%

Lexicon Pharmaceuticals stock opened at $2.43 on Monday. The stock has a market cap of $1.08 billion, a PE ratio of -16.20 and a beta of 1.08. The company has a debt-to-equity ratio of 0.29, a quick ratio of 13.29 and a current ratio of 13.37. Lexicon Pharmaceuticals has a one year low of $1.02 and a one year high of $2.68. The stock has a fifty day moving average of $2.22 and a 200 day moving average of $1.88.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%. The firm had revenue of $0.69 million for the quarter, compared to the consensus estimate of $3.99 million.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of LXRX. Siren L.L.C. increased its holdings in Lexicon Pharmaceuticals by 13.8% in the 1st quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company’s stock worth $69,113,000 after acquiring an additional 5,384,615 shares in the last quarter. Renaissance Technologies LLC raised its stake in Lexicon Pharmaceuticals by 508.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company’s stock worth $2,497,000 after acquiring an additional 1,337,246 shares during the period. UBS Group AG lifted its holdings in Lexicon Pharmaceuticals by 752.1% during the fourth quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock valued at $3,458,000 after purchasing an additional 2,654,315 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in Lexicon Pharmaceuticals during the first quarter valued at approximately $1,170,000. Finally, Ishara Investments LP bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $1,012,000. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.